JAK Inhibitor Selection in Myelofibrosis: A Clinical Decision-Making Approach
home / expert-perspective-tumor-board / jak-inhibitor-selection-in-myelofibrosis-a-clinical-decision-making-approach
Aaron Gerds, MD; Jeanne Palmer, MD; Prithviraj Bose, MD; and Jonathan Abbas, MD, examine the comprehensive management of myelofibrosis, from molecular mechanisms through various disease stages, focusing on risk stratification, treatment sequencing, quality-of-life outcomes, and the integration of emerging therapies into evidence-based clinical practice.
EP. 2: Patient-Centered Care in Myelofibrosis: Managing Expectations and Quality-of-Life Outcomes
January 27th 2025Panelists discuss how health care providers can optimize quality-of-life and treatment outcomes for patients with myelofibrosis through comprehensive symptom management, shared decision-making, and careful attention to patient goals and expectations.
Watch
